AMCP's Adam Colborn Talks Court Ruling's Impact on Employer Pharmacy Benefits and CalRX Insulin Cap | AMCP Nexus 2023

News
Article

In a session presented at the AMCP Nexus 2023 conference in Orlando, Adam Colborn, JD, director of Government Relations at AMCP, discussed how the recent ERISA preemption rule influenced employer pharmacy benefits, and also highlighted a policy that hasn't received much attention in the managed care pharmacy space: California's CalRx Biosimilar Insulin Initiative.

Second of two parts


In a session presented at the AMCP Nexus 2023 conference in Orlando, Adam Colborn, JD, director of Government Relations at AMCP, discussed how the recent ERISA preemption rule influenced employer pharmacy benefits, and also highlighted a policy that hasn't received much attention in the managed care pharmacy space: California's CalRx Biosimilar Insulin Initiative.

The CalRx initiative announced they plan to offer insulin which will be capped at $30 for a month’s supply.

Related: Adam Colborn of AMCP Gives a Legislative, Regulatory Update in the Pharmacy Space and Shares Concern on OOP Medicare Part D Copay Assistance | AMCP Nexus 2023

"I think it’s the kind of program that we could see other states, particularly those held by Democrats, in the future, like Illinois or New York, adopting the program," he said.

"It's something that I'll definitely be keeping an eye on as it develops over the next couple of years," Colborn added. "I think other folks in the pharmacy care world should be paying attention as well."

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.